Saturday 17 October 2026
Export IDXX’s income statement to Excel — free account
IDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.
560.36
13.18
+2.41%
Follow IDXX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
64.63% | 66.20% | 72.92% | 74.21% | |
Piotroski F-Score |
8 | 8 | 8 | 9 | |
| 30.50% | 31.89% | 33.19% | 33.65% | ||
ROIC |
43.47% | 45.33% | 48.68% | 48.87% | |
Return on Tangible Assets |
106.50% | 104.65% | 122.43% | 119.33% | |
Average Days of Receivables |
49.65 | 46.85 | 49.55 | 50.27 | |
Free Cash Flow per Share |
10.78 | 11.89 | 13.28 | 15.67 | |
Free Cash Flow |
863.22 | 956.58 | 1,058.11 | 1,237.09 | |
Capital Expenditures |
(224.85) | (225.23) | (151.98) | (134.42) | |
| Other line items | |||||
Cash ROIC |
37.63% | 42.79% | 47.95% | 54.75% | |
Accounts Receivable Turnover |
7.73 | 8.39 | 7.86 | 7.67 | |
Accounts Payable Turnover |
13.70 | 14.64 | 13.49 | 13.92 | |
Inventory Turnover |
4.08 | 4.33 | 4.34 | 4.36 | |
Average Days of Payables |
27.97 | 24.51 | 28.12 | 27.56 | |
Days of Inventory on Hand |
89.59 | 83.86 | 82.73 | 83.59 | |
Tax Rate |
(0.19) | (0.20) | (0.20) | (0.20) | |
Research and Development Expense of Revenue |
5.81% | 5.84% | 5.80% | 5.74% | |
Selling, General and Administrative Expense of Revenue |
24.57% | 24.36% | 24.63% | 24.67% | |
Share Based Compensation of Revenue |
1.40% | 1.39% | 1.39% | 1.38% | |
Interest Coverage |
35.17 | 35.01 | 36.12 | 38.60 | |
Operating CF/Net income |
1.06 | 1.12 | 1.10 | 1.20 | |
Depreciation/Fixed assets |
0.19 | 0.19 | 0.20 | 0.21 | |
Capex/Depreciation |
(1.60) | (1.55) | (1.02) | (0.87) | |
Revenue per Share |
52.03 | 53.51 | 55.82 | 57.67 | |
Operating CF per Share |
13.58 | 14.69 | 15.19 | 17.37 | |
Capex per Share |
(2.81) | (2.80) | (1.91) | (1.70) | |
Capex to Sales |
0.05 | 0.05 | 0.03 | 0.03 |
Columns are period end dates